AU2002341266B2 - Use of HMGB1 for the activation of dendritic cells - Google Patents
Use of HMGB1 for the activation of dendritic cells Download PDFInfo
- Publication number
- AU2002341266B2 AU2002341266B2 AU2002341266A AU2002341266A AU2002341266B2 AU 2002341266 B2 AU2002341266 B2 AU 2002341266B2 AU 2002341266 A AU2002341266 A AU 2002341266A AU 2002341266 A AU2002341266 A AU 2002341266A AU 2002341266 B2 AU2002341266 B2 AU 2002341266B2
- Authority
- AU
- Australia
- Prior art keywords
- apc
- antigen
- protein
- hmgb1
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2001MI001986A ITMI20011986A1 (it) | 2001-09-25 | 2001-09-25 | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
ITMI2001A001986 | 2001-09-25 | ||
PCT/IB2002/004080 WO2003026691A2 (en) | 2001-09-25 | 2002-09-25 | Use of hmgb1 for the activation of dendritic cells |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002341266A1 AU2002341266A1 (en) | 2003-06-26 |
AU2002341266B2 true AU2002341266B2 (en) | 2007-11-15 |
Family
ID=11448420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002341266A Ceased AU2002341266B2 (en) | 2001-09-25 | 2002-09-25 | Use of HMGB1 for the activation of dendritic cells |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040242481A1 (it) |
EP (1) | EP1432441B1 (it) |
JP (1) | JP2005508913A (it) |
AT (1) | ATE437652T1 (it) |
AU (1) | AU2002341266B2 (it) |
CA (1) | CA2461091A1 (it) |
DE (1) | DE60233147D1 (it) |
IT (1) | ITMI20011986A1 (it) |
WO (1) | WO2003026691A2 (it) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050112121A1 (en) * | 1992-04-30 | 2005-05-26 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
GB0226251D0 (en) * | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
EP1899376A2 (en) | 2005-06-16 | 2008-03-19 | The Feinstein Institute for Medical Research | Antibodies against hmgb1 and fragments thereof |
US7829097B2 (en) | 2006-02-06 | 2010-11-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of HMGB1 for protection against ischemia reperfusion injury |
US20090202500A1 (en) * | 2006-10-30 | 2009-08-13 | Genomix Co., Ltd. | Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues |
US20100173277A1 (en) * | 2007-02-15 | 2010-07-08 | Fukuoka University | Agent for Suppressing Rejection in Organ Transplantation Comprising Anti-HMGB-1 Antibody |
TW200902063A (en) | 2007-02-15 | 2009-01-16 | Univ Kumamoto | Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient |
JP5241518B2 (ja) | 2007-02-15 | 2013-07-17 | 国立大学法人九州大学 | 抗hmgb−1抗体を含む間質性肺疾患治療剤 |
CA3156538C (en) | 2007-11-01 | 2023-12-12 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
RU2571230C2 (ru) | 2008-04-30 | 2015-12-20 | Дженомикс Ко., Лтд. | Способ сбора функциональных клеток in vivo с высокой эффективностью |
JP5660889B2 (ja) | 2008-04-30 | 2015-01-28 | 株式会社ジェノミックス | 末梢循環への骨髄由来多能性幹細胞動員薬 |
BRPI0911436A2 (pt) * | 2008-04-30 | 2016-07-12 | Genomix Co Ltd | vetores contendo o dna codificando as proteínas s100a8 e s100a9 e sua utilização para confecção de composições farmacêuticas para promoção da regeneração funcional de tecido lesionado |
RU2599448C2 (ru) | 2009-10-28 | 2016-10-10 | Дженомикс Ко., Лтд. | Средства для стимуляции регенерации тканей путем привлечения мезенхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь |
ES2643646T3 (es) | 2010-01-21 | 2017-11-23 | The Board Of Trustees Of The University Of Arkansas | Vectores de vacuna y métodos para potenciar las respuestas inmunitarias |
AU2011235296C1 (en) | 2010-03-29 | 2017-05-04 | Nationwide Children's Hospital, Inc. | Compositions and methods for the removal of biofilms |
EP2579901B1 (en) * | 2010-06-09 | 2019-08-07 | The Board of Trustees of The University of Arkansas | Vaccine and methods to reduce campylobacter infection |
EP2613797B1 (en) * | 2010-09-09 | 2015-11-04 | University Of Southern California | Compositions and methods for the removal of biofilms |
EP2703487B1 (en) | 2011-04-26 | 2018-06-27 | Genomix Co., Ltd. | Peptide for inducing regeneration of tissue and use thereof |
WO2012170742A2 (en) * | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
MX361259B (es) | 2012-10-25 | 2018-11-30 | Univ Osaka | Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio. |
SG11201503215XA (en) | 2012-10-25 | 2015-06-29 | Genomix Co Ltd | Novel method for treating spinal cord injury using hmgb1 fragment |
NZ711019A (en) | 2013-02-14 | 2019-07-26 | Univ Arkansas | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
BR112015023024B1 (pt) | 2013-03-15 | 2022-04-19 | The Board Of Trustees Of The University Of Arkansas | Vetor de vacina e composições farmacêuticas compreendendo o mesmo |
US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
US9745366B2 (en) | 2013-09-23 | 2017-08-29 | University Of Southern California | Compositions and methods for the prevention of microbial infections |
US10233234B2 (en) | 2014-01-13 | 2019-03-19 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
US11248040B2 (en) | 2013-09-26 | 2022-02-15 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
AU2016303688B2 (en) | 2015-07-31 | 2023-06-15 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
GB201600075D0 (en) | 2016-01-03 | 2016-02-17 | Glaxosmithkline Biolog Sa | Immunogenci composition |
WO2017192671A1 (en) | 2016-05-03 | 2017-11-09 | The Board Of Trustees Of The University Of Arkansas | Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same |
WO2018047917A1 (ja) * | 2016-09-09 | 2018-03-15 | 国立大学法人 東京大学 | Hmgタンパク質と抗cd4抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果 |
MX2019008949A (es) | 2017-01-27 | 2019-10-07 | Stemrim Inc | Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica. |
CA3056088A1 (en) | 2017-03-15 | 2018-09-20 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
JPWO2019107530A1 (ja) | 2017-12-01 | 2020-11-26 | 株式会社ステムリム | 炎症性腸疾患の治療薬 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000047104A2 (en) * | 1999-02-11 | 2000-08-17 | North Shore-Long Island Jewish Research Institute | Antagonists of hmg1 for treating inflammatory conditions |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5214131A (en) * | 1988-05-06 | 1993-05-25 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, modified peptides and production thereof |
US5091176A (en) * | 1988-11-02 | 1992-02-25 | W. R. Grace & Co.-Conn. | Polymer-modified peptide drugs having enhanced biological and pharmacological activities |
JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
US5811512A (en) * | 1991-08-22 | 1998-09-22 | The Trustees Of The University Of Pennsylvania | Non-peptide peptidomimetics and related cyclic hexapeptides |
US5580853A (en) * | 1994-03-22 | 1996-12-03 | New England Deaconess Hospital | Modified polypeptides with increased biological activity |
US5891418A (en) * | 1995-06-07 | 1999-04-06 | Rhomed Incorporated | Peptide-metal ion pharmaceutical constructs and applications |
FR2739292B1 (fr) * | 1995-09-28 | 1997-10-31 | Rhone Poulenc Rorer Sa | Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations |
IT1299583B1 (it) * | 1998-05-19 | 2000-03-16 | Vander Way Limited | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica |
US6100090A (en) * | 1999-06-25 | 2000-08-08 | Isis Pharmaceuticals Inc. | Antisense inhibition of PI3K p85 expression |
-
2001
- 2001-09-25 IT IT2001MI001986A patent/ITMI20011986A1/it unknown
-
2002
- 2002-09-25 AU AU2002341266A patent/AU2002341266B2/en not_active Ceased
- 2002-09-25 US US10/489,878 patent/US20040242481A1/en not_active Abandoned
- 2002-09-25 EP EP02775057A patent/EP1432441B1/en not_active Expired - Lifetime
- 2002-09-25 JP JP2003530326A patent/JP2005508913A/ja active Pending
- 2002-09-25 WO PCT/IB2002/004080 patent/WO2003026691A2/en active Application Filing
- 2002-09-25 CA CA002461091A patent/CA2461091A1/en not_active Abandoned
- 2002-09-25 DE DE60233147T patent/DE60233147D1/de not_active Expired - Lifetime
- 2002-09-25 AT AT02775057T patent/ATE437652T1/de not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000047104A2 (en) * | 1999-02-11 | 2000-08-17 | North Shore-Long Island Jewish Research Institute | Antagonists of hmg1 for treating inflammatory conditions |
Also Published As
Publication number | Publication date |
---|---|
WO2003026691A2 (en) | 2003-04-03 |
EP1432441B1 (en) | 2009-07-29 |
DE60233147D1 (de) | 2009-09-10 |
ITMI20011986A1 (it) | 2003-03-25 |
EP1432441A2 (en) | 2004-06-30 |
CA2461091A1 (en) | 2003-04-03 |
ITMI20011986A0 (it) | 2001-09-25 |
JP2005508913A (ja) | 2005-04-07 |
WO2003026691A3 (en) | 2003-05-30 |
ATE437652T1 (de) | 2009-08-15 |
US20040242481A1 (en) | 2004-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002341266B2 (en) | Use of HMGB1 for the activation of dendritic cells | |
AU2002341266A1 (en) | Use of HMGB1 for the activation of dendritic cells | |
JP3581366B2 (ja) | 免疫原のリソソーム標的 | |
JP4422903B2 (ja) | 癌抑制遺伝子wt1の産物に基づく癌抗原 | |
US20060111287A1 (en) | Acetylated protein | |
JP4900884B2 (ja) | 腫瘍抗原 | |
PT2260862E (pt) | Composições e métodos para tratar tumores que apresentam antigénios de survivina | |
JP2003521245A (ja) | ペプチドおよび核酸組成物を使用する、前立腺癌抗原に対する細胞性免疫応答の誘導 | |
JP2008245651A (ja) | 改良されたワクチン | |
US8258261B2 (en) | Induction of tumor immunity by variants of folate binding protein | |
CA2110055C (en) | T cell receptor peptides as therapeutics for immune-related disease | |
CA2346496A1 (en) | Novel th2-specific molecules and uses thereof | |
JP4945444B2 (ja) | Hla−a3スーパータイプアレル分子陽性前立腺癌患者に対する癌ワクチン候補となる前立腺関連蛋白由来ペプチド | |
EP0964697B1 (en) | Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene | |
Odales et al. | Antitumor efficacy of MUC1-derived variable epitope library treatments in a mouse model of breast cancer | |
JP2003517310A (ja) | ペプチドおよび核酸組成物を使用する、mage2/3に対する細胞性免疫応答の誘導 | |
US20040241152A1 (en) | Methods for inducing an immune response with an elevated th1/th2 ratio, by intracellular induction of nfkappab | |
US20080095789A1 (en) | Vaccine | |
US20090124557A1 (en) | Compositions and methods for treating cancer | |
JP2003516131A (ja) | ペプチドおよび核酸組成物を使用する、p53に対する細胞性免疫応答の誘導 | |
EP2134750B1 (en) | Ig-p consensus gene vaccination protects from antibody-dependent immune pathology in autoimmune disease | |
WO2002088304A2 (en) | Compositions and methods for suppressing immune responses | |
Karakikes et al. | OPEN POSTERS Accessory molecules | |
Rynda | Low dose tolerance vaccine platform, reovirus protein sigma 1 and treatment of autoimmunity | |
Hampton | Identification and characterization of tumor-associated antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |